title: PET/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology.
abstract: OBJECTIVE
  PET/CT with (18)F-FDG shows metabolically active disease and is widely used for the diagnosis and follow-up of patients with cancer. Nonmetabolically active renal pathology may be missed without close attention to the CT portion of the study, whereas metabolically active pathology may be missed on PET because of physiologic tracer excretion in the kidneys. This article illustrates primary lesions of the kidney on FDG PET/CT with emphasis on key anatomic features and the appearance of tracer uptake.
  
  
  CONCLUSIONS
  Close attention to both the FDG PET and CT portions of the study is essential to interpret renal pathology correctly on FDG PET/CT examinations.
authors: Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA 02115, USA. kzukotynski@partners.org
authors: Katherine
authors: K
authors: Zukotynski
authors: Aaron
authors: A
authors: Lewis
authors: Kevin
authors: K
authors: O'Regan
authors: Heather
authors: H
authors: Jacene
authors: Christopher
authors: C
authors: Sakellis
authors: Katherine
authors: K
authors: Krajewski
authors: David
authors: D
authors: Israel
mesh_terms: D003937:Diagnosis, Differential; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18